Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse

Chemotherapy is a standard treatment for pediatric acute lymphoblastic leukemia (ALL), which sometimes relapses with chemoresistant features. However, whether acquired drug-resistance mutations in relapsed ALL pre-exist or are induced by treatment remains unknown. Here we provide direct evidence of...

Full description

Bibliographic Details

Published in:	Nature cancer Vol. 2; no. 8; pp. 819 - 834
Main Authors:	Yang, Fan, Brady, Samuel W., Tang, Chao, Sun, Huiying, Du, Lijuan, Barz, Malwine J., Ma, Xiaotu, Chen, Yao, Fang, Houshun, Li, Xiaomeng, Kolekar, Pandurang, Pathak, Omkar, Cai, Jiaoyang, Ding, Lixia, Wang, Tianyi, von Stackelberg, Arend, Shen, Shuhong, Eckert, Cornelia, Klco, Jeffery M., Chen, Hongzhuan, Duan, Caiwen, Liu, Yu, Li, Hui, Li, Benshang, Kirschner-Schwabe, Renate, Zhang, Jinghui, Zhou, Bin-Bing S.
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.08.2021
Subjects:	Chemotherapy Child Cloning Humans Mutagenesis Mutation Neoplastic Syndromes, Hereditary Pediatrics Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Primary Immunodeficiency Diseases Recurrence Tumor Suppressor Protein p53 - genetics Tumors United States > US
ISSN:	2662-1347, 2662-1347
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!